Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Immunicom Inc. focuses its patent filings in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action that requires a formal response. This workload is handled by 1 distinct examiner, which indicates a singular focus for the current prosecution efforts. Furthermore, the active matter is situated within 1 distinct art unit, ensuring that the technical review is conducted by a specialized group within the patent office.
The busiest examiner for this portfolio is NATARAJAN, MEERA, who is responsible for 1 busiest examiner pending office action. Because the total number of pending office actions is 1, this examiner is currently managing the whole of the company's active prosecution. Practitioners should analyze the specific examination patterns of NATARAJAN, MEERA to better prepare for potential hurdles in the Biotechnology & Pharmaceuticals sector. The presence of 1 distinct examiner and 1 distinct art unit allows for a streamlined approach to prosecution without the complexity of coordinating across different technical departments.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NATARAJAN, MEERA | 1 | 62.5% | +18.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18377669 | INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESIS | NATARAJAN, MEERA | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18377669 | INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESIS | NATARAJAN, MEERA | 1643 | §103§112DP | Non-Final OA | — | Pending | Oct 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial